r-tPA和尿激酶对急性心肌梗死再灌注心律失常的影响

The Comparative Analysis of Reperfusion Arrhythmias in Thrombolytic Treatment with Recombinant Tissue Plasminogen Activator as Compared with Urokinase on Acute Myocardial Infarction

目的探讨组织型纤维蛋白溶酶原激活剂(r-tPA)和尿激酶两者对急性心肌梗死再灌注心律失常的影响。方法符合急性心肌梗死溶栓条件的患者82例,分成两组分别应用r-tPA和尿激酶溶栓,观察再灌注性心律失常的变化。结果r-tPA组与尿激酶组室速、室颤的发生率有显著性差异(P<0.05),其它再灌注性心律失常两组差异无显著性(P>0.05)。结论应用r-tPA溶栓治疗急性心肌梗死时容易发生恶性再灌注性心律失常,但仍是目前最好的溶栓剂。

Objective To find out the effect for reperfusion arrhythmias in the patient with Acute Myocardial Infarction(AMI) with treatment with Recombinant Tissue Plasminogen Activator (r-tPA) as compared with Urokinase (UK).Methods Eighty two patients with AMI,which fit the indication of thrombolysis were divided into 2 groups randomly,which were treated with r-tPA and UK respectively,observe the changes of reperfusion arrhythmias.Results There was significant difference in the incidence of ventricular tachycardia and ventricular fibrillation (P<0.05),there was no significant difference in the incidence of other types of arrhymias(P>0.05).Conclusion Use r-tPA as a drugs in thrombolysis in treating AMI,was easier to occur fatal arrhythmias,but r-tPA was still the best thrombolytic drug in treating AMI.